1. Adaszewska A, Woźniak K, Kaliñska-Bienias A, et al. Diagnostics of autoimmune blistering disorders: an experience of a single tertiary referral centre. Adv Dermatol Allergol 2022; 39: 446-53.
2.
Aguado Vázquez Á, Estébanez Corrales A, Melgosa Ramos FJ, et al. Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience. Clin Exp Dermatol 2024; 49: 1002-6.
3.
Powers CM, Thakker S, Gulati N, et al. Bullous pemphigoid: a practical approach to diagnosis and management in the modern era. J Am Acad Dermatol 2025; 92: 1337-50.
4.
Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2022; 36: 1689-704.
5.
Cao P, Xu W, Zhang L. Rituximab, omalizumab, and dupilumab treatment outcomes in bullous pemphigoid: a systematic review. Front Immunol 2022; 13: 928621.
6.
Altan Ferhatoglu Z, Yucesoy SN, Ak T, Demir Y. Omalizumab in the treatment of bullous pemphigoid: a single-center series of 15 cases. Medicine 2024; 103: e38684.
7.
Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol 2012; 66: 479-85.
8.
Kalinska-Bienias A, Kowalczyk E, Jagielski P, et al. Clinical characteristics of pruritus in patients with bullous pemphigoid: a preliminary questionnaire-based study. Adv Dermatol Allergol 2020; 37: 938-42.
9.
Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol 2019; 94: 133-46.
10.
Bahloul D, Dubucq H, Thomas RB, et al. Burden of disease of bullous pemphigoid: a targeted literature review. Dermatology 2024; 240: 823-32.
11.
Werth VP, Murrell DF, Joly P, et al. Bullous pemphigoid burden of disease, management and unmet therapeutic needs. J Eur Acad Dermatol Venereol 2025; 39: 290-300.
12.
Huttelmaier J, Benoit S, Goebeler M. Comorbidity in bullous pemphigoid: up-date and clinical implications. Front Immunol 2023; 14: 1196999.
13.
Akbarialiabad H, Schmidt E, Patsatsi A, et al. Bullous pemphigoid. Nat Rev Dis Primers 2025; 11: 12.
14.
Klepper EM, Robinson HN. Dupilumab for the treatment of nivolumab-induced bullous pemphigoid: a case report and review of the literature. Dermatol Online J 2021; 27. doi: 10.5070/D327955136.
15.
Ling X, Shou X, Lou Y, et al. Research progress of omalizumab in the treatment of bullous pemphigoid. J Dermatol 2023; 50: 575-87.
16.
Alexandre M, Bohelay G, Gille T, et al. Rapid disease control in first-line therapy-resistant mucous membrane pemphigoid and bullous pemphigoid with omalizumab as add-on therapy: a case series of 13 patients. Front Immunol 2022; 13: 874108.
17.
Kwon IJ, Kim T, Yoo DS, et al. Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid. J Dermatol 2023; 50: 705-9.
18.
Ujiie H, Iwata H, Yamagami J, et al. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol 2019; 46: 1102-35.
19.
Karakioulaki M, Eyerich K, Patsatsi A. Advancements in bullous pemphigoid treatment: a comprehensive pipeline update. Am J Clin Dermatol 2024; 25: 195-212.
20.
Chebani R, Lombart F, Chaby G, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. Br J Dermatol 2024; 190: 258-65.
21.
Clapé A, Muller C, Gatouillat G, et al. Mucosal involvement in bullous pemphigoid is mostly associated with disease severity and to absence of anti-BP230 autoantibody. Front Immunol 2018; 9: 479.
22.
Zhang L, Chen Z, Wang L, Luo X. Bullous pemphigoid: the role of type 2 inflammation in its pathogenesis and the prospect of targeted therapy. Front Immunol 2023; 14: 1115083.
23.
Bowszyc-Dmochowska M, Dmochowski M. Immediate hypersensitivity phenomena in bullous pemphigoid: critical concepts. J Med 2002; 33: 189-98.
24.
Fang H, Li Q, Wang G. The role of T cells in pemphigus vulgaris and bullous pemphigoid. Autoimmun Rev 2020; 19: 102661.
25.
Abdat R, Waldman RA, de Bedout V, et al. Dupilumab as a novel therapy for bullous pemphigoid: a multicenter case series. J Am Acad Dermatol 2020; 83: 46-52.
26.
Hamilton JD, Suárez-Fariñas M, Dhingra N, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 2014; 134: 1293-300.
27.
Avallone G, Maronese CA, Zussino M, et al. Effectiveness of dupilumab and omalizumab in bullous pemphigoid: a nationwide retrospective cohort study. J Dermatol 2025; 52: 983-1000.
28.
Murrell DF, Joly P, Werth VP, et al. Study design of a phase 2/3 randomized controlled trial of dupilumab in adults with bullous pemphigoid: LIBERTY-BP ADEPT. Adv Ther 2024; 41: 2991-3002.
29.
Granados-Betancort E, Sánchez-Díaz M, Muñoz-Barba D, Arias-Santiago S. Omalizumab and dupilumab for the treatment of bullous pemphigoid: a systematic review. J Clin Med 2024; 13: 4844.
30.
D’Aguanno K, Gabrielli S, Ouchene L, et al. Omalizumab for the treatment of bullous pemphigoid: a systematic review of efficacy and safety. J Cutan Med Surg 2022; 26: 404-13.
31.
Levi M. Inflammation and coagulation. In: Inflammation: From Molecular and Cellular Mechanisms to the Clinic. Cavaillon JM, Singer M (eds). Wiley-VCH Verlag GmbH & Co. Weinheim, Germany 2018; 833-60.
